Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug

Status:
RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug

PHASE3

NPO Petrovax